Download PDF

1. Company Snapshot

1.a. Company Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases.Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers.


C4 Therapeutics, Inc.has strategic collaborations with F.Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC.


The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Show Full description

1.b. Last Insights on CCCC

C4 Therapeutics' recent performance has been negatively driven by a Q4 loss of $0.49 per share, missing revenue estimates. The company's planning activities for the next phase of Cemsidomide clinical development in multiple myeloma and non-Hodgkin's lymphoma trials expected to initiate in early 2026 indicate a positive future outlook, but the current results weigh on the stock. The heavy selling pressure might have exhausted, and the stock is technically in oversold territory, potentially setting the stage for a trend reversal."

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

Nov -26

Source: seekingalpha.com

Card image cap

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov -25

Source: globenewswire.com

Card image cap

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

Nov -12

Source: seekingalpha.com

Card image cap

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates

Nov -06

Source: zacks.com

Card image cap

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov -06

Source: globenewswire.com

Card image cap

Brookstone Capital Management Purchases Shares of 29,325 C4 Therapeutics, Inc. $CCCC

Oct -30

Source: defenseworld.net

Card image cap

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

Oct -16

Source: globenewswire.com

Card image cap

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Oct -01

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.70%)

6. Segments

Targeted Protein Degradation

Expected Growth: 11.7%

C4 Therapeutics' Targeted Protein Degradation growth is driven by increasing adoption in oncology and neurology, strong partnerships with pharma and biotech companies, and a robust pipeline of novel degraders. The 11.7% growth rate is also fueled by advancements in CRISPR-Cas9 gene editing technology and growing demand for precision medicine.

7. Detailed Products

CFT7455

A small molecule inhibitor of the ubiquitin-proteasome pathway, targeting the ubiquitin E3 ligase, Cereblon.

CFT8634

A small molecule inhibitor of the ubiquitin-proteasome pathway, targeting the ubiquitin E3 ligase, SPOP.

CRBN-based E3 ligase modulators

Small molecule modulators of the Cereblon ubiquitin E3 ligase, targeting specific neo-substrates for degradation.

SPOP-based E3 ligase modulators

Small molecule modulators of the SPOP ubiquitin E3 ligase, targeting specific neo-substrates for degradation.

8. C4 Therapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

C4 Therapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and other diseases.

Bargaining Power Of Customers

C4 Therapeutics, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual patients and the complexity of the pharmaceutical industry.

Bargaining Power Of Suppliers

C4 Therapeutics, Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and equipment, but also the complexity of the pharmaceutical industry.

Threat Of New Entrants

C4 Therapeutics, Inc. has a high threat of new entrants due to the attractiveness of the pharmaceutical industry and the potential for new companies to enter the market.

Intensity Of Rivalry

C4 Therapeutics, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 22.38%
Debt Cost 3.95%
Equity Weight 77.62%
Equity Cost 20.11%
WACC 16.50%
Leverage 28.84%

11. Quality Control: C4 Therapeutics, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Zevra Therapeutics

A-Score: 3.9/10

Value: 4.6

Growth: 4.0

Quality: 5.8

Yield: 0.0

Momentum: 6.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
TRACON Pharmaceuticals

A-Score: 3.7/10

Value: 9.6

Growth: 6.9

Quality: 5.2

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Arvinas

A-Score: 3.5/10

Value: 8.4

Growth: 4.4

Quality: 5.4

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Vericel

A-Score: 3.4/10

Value: 1.0

Growth: 7.9

Quality: 6.1

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
Orgenesis

A-Score: 2.9/10

Value: 7.7

Growth: 4.2

Quality: 5.8

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
C4 Therapeutics

A-Score: 2.8/10

Value: 7.8

Growth: 2.4

Quality: 4.7

Yield: 0.0

Momentum: 1.0

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.67$

Current Price

2.67$

Potential

-0.00%

Expected Cash-Flows